MNPR Triangle 2.JPG
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
August 03, 2021 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
MNPR Triangle 2.JPG
Monopar Appoints Octávio Costa, MD, as Chief Medical Officer
July 12, 2021 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
MNPR Triangle 2.JPG
Monopar to Present Results from Analysis of Oropharyngeal Cancer Patients in Completed Phase 2 Validive® Trial at MASCC/ISOO
June 24, 2021 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., June 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
MNPR Triangle 2.JPG
Monopar公布新候选药物MNPR-202,并与新加坡国立大学签订癌症临床前评估合作协议
June 03, 2021 09:19 ET | Monopar Therapeutics Inc.
伊利诺伊州威尔梅特, June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.(纳斯达克股票代码:MNPR)是一家临床阶段生物制药公司,主要专注于开发延长癌症患者寿命或提高其生活质量的专有疗法。公司今日宣布,已与新加坡国立大学(NUS)下属新加坡癌症科学研究所(CSI...
MNPR Triangle 2.JPG
Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
June 03, 2021 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., June 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
mono.jpg
Monopar和NorthStar宣布提交保护MNPR-101放射疗法的物质构成专利申请 伊利诺伊州威尔梅特和威斯康星州贝洛伊特, May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.(纳斯达克股票代码:MNPR)和NorthStar Medical Radioisotopes...
mono.jpg
Monopar and NorthStar Announce Filing of Composition of Matter Patent Protecting MNPR-101 Radiotherapeutic WILMETTE, Ill. and BELOIT, Wis., May 26, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
mono.jpg
Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
May 24, 2021 08:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional...
mono.jpg
Monopar和NorthStar宣布就有前途的放射性药物探索提交专利申请
May 24, 2021 08:00 ET | Monopar Therapeutics Inc.
伊利诺伊州威尔米特和威斯康星州贝洛伊特, May 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc.(纳斯达克股票代码:MNPR)和NorthStar Medical Radioisotopes...
mono.jpg
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
May 13, 2021 16:42 ET | Monopar Therapeutics Inc.
First Patient Dosed in Validive® Phase 2b/3 VOICE Clinical TrialCamsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer...